Clinical trials: Allogeneic Bone Marrow Transplantation
Myelofibrosis, Acute Myelogenous Leukemia
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).
- Trial name
- NCT04709458
- Testing
- TBX-2400
- Where
- 2 sites in Croatia, Italy
- Volunteers
- 10 people
- Sponsor
- Taiga Biotechnologies, Inc.
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem cell transplantation in patients with high-risk MDS/AML.
- Trial name
- NCT02124174
- Testing
- Vidaza and Valproic Acid
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Patrick Stiff
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
- Trial name
- NCT01433965
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Davis
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: efprezimod alfa vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- CATHY (NCT04095858)
- Testing
- Efprezimod alfa, Methotrexate, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Leukemia, Hodgkin Lymphoma
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and…
- Conditions
- Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT00556452
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan Rogel Cancer Center
Crohn Disease
Crohn's Allogeneic Transplant Study
This phase II trial studies how well giving a donor bone marrow transplant (BMT) works in treating patients with refractory Crohn's Disease.
- Trial name
- CATS (NCT01570348)
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes
CyFluATG in Lower Risk MDS
To evaluate the efficacy of the conditioning regimen with cyclophosphamide, fludarabine, and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation (HCT) in patients with lower risk myelodysplastic…
- Trial name
- NCT06098326
- Testing
- cyclophosphamide, fludarabine, and antithymocyte globulin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
A 5 day course of fludarabine and cytarabine (FA) will be administered followed by full intensity conditioning regimen (Bucy) in the setting of allogeneic stem cell transplantation (SCT).
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT02328950
- Testing
- Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients.
- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT05534620
- Testing
- Treosulfan, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- medac GmbH
Osteogenesis Imperfecta
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III.
- Trial name
- NCT00705120
- Testing
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Lymphoma
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006350
- Testing
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases.
- Conditions
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome
- Trial name
- NCT06793410
- Testing
- Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9®
- Where
- 5 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Vastra Gotaland Region
Myeloid Neoplasms With Myelofibrosis
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to…
- Trial name
- JAK-PeriMF (NCT07883382)
- Testing
- gecacitinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML)
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid, Myeloid Leukemias, Acute
- Trial name
- HALO-SCT (NCT07205523)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yigeng Cao,MD,PhD
Anemia, Aplastic, Amegakaryocytic Thrombocytopenia
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
Due to an overall and disease free survival of 85% to 100%, allogeneic blood or bone marrow stem cell transplantation using an HLA matched sibling donor is the therapy of choice for patients with severe aplastic anemia (SAA).
- Conditions
- Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
- Trial name
- NCT00244010
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Adult, Graft Versus Host Disease
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
The investigators aimed to reveal the relationship between serum markers of pyroptosis, GVHD biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for AML and developed…
- Conditions
- Acute Myeloid Leukemia, Adult, Graft Versus Host Disease, Endothelial Dysfunction
- Trial name
- NCT06200441
- Where
- Turkey (Türkiye)
- Sponsor
- Ugur Arzu Kulu
Leukemia, Myelodysplastic Syndromes
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Peripheral stem cell transplantation may be an effective treatment for leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed following bone marrow transplantation.
- Trial name
- NCT00002832
- Testing
- Filgrastim, Cyclosporine, Decitabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity.
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT07634536
- Testing
- VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Myeloid Leukemia, Chronic
Effect of 2nd Gen TKI in CML
Stem cell transplantation will continue to be a treatment option for patients with chronic myeloid leukaemia, despite the introduction of tyrosine kinase inhibitors.
- Trial name
- NCT02222272
- Where
- 10 sites in Denmark, Finland and 7 more
- Volunteers
- 432 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes